BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 22699454)

  • 1. Prognostic utility of intact immunoglobulin Ig'κ/Ig'λ ratios in multiple myeloma patients.
    Bradwell A; Harding S; Fourrier N; Mathiot C; Attal M; Moreau P; Harousseau JL; Avet-Loiseau H
    Leukemia; 2013 Jan; 27(1):202-7. PubMed ID: 22699454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of monoclonal gammopathies by nephelometric measurement of individual immunoglobulin kappa/lambda ratios.
    Bradwell AR; Harding SJ; Fourrier NJ; Wallis GL; Drayson MT; Carr-Smith HD; Mead GP
    Clin Chem; 2009 Sep; 55(9):1646-55. PubMed ID: 19617289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of the noninvolved pair of the myeloma isotype correlates with poor survival in newly diagnosed and relapsed/refractory patients with myeloma.
    Ludwig H; Milosavljevic D; Berlanga O; Zojer N; Hübl W; Fritz V; Harding S
    Am J Hematol; 2016 Mar; 91(3):295-301. PubMed ID: 26662888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Assessment of Heavy/ Light Chain Pairs of Immunoglobulin (Hevylite assay) -  Benefit for Stratification of Multiple Myeloma?].
    Ščudla V; Lochaman P; Pika T; Zapletalová J; Minařík J; Bačovský J
    Klin Onkol; 2015; 28(5):359-69. PubMed ID: 26480864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Analysis of serum free light chains κ/λ ratio and heavy/light chain pairs of immunoglobulin to the stratification of multiple myeloma according to Mayo Stratification of Myeloma and Revised International Staging System].
    Ščudla V; Balcárková J; Lochman P; Vincová M; Pika T; Minařík J; Zapletalová J; Jarošová M
    Vnitr Lek; 2016 Apr; 62(4):269-80. PubMed ID: 27250604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship of differences in immunoglobulin heavy/light chain pairs (Hevylite), selected laboratory parameters and stratification systems in different immunochemical types of multiple myeloma.
    Scudla V; Lochman P; Pika T; Minarik J; Zapletalova J; Bacovsky J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2016 Mar; 160(1):84-93. PubMed ID: 26365929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IgA kappa/IgA lambda heavy/light chain assessment in the management of patients with IgA myeloma.
    Boyle EM; Fouquet G; Guidez S; Bonnet S; Demarquette H; Dulery R; Herbaux C; Noel MP; Manier S; Schraen S; Onraed B; Faucompré JL; Hennache B; Petillon MO; Mathiot C; Avet-Loiseau H; Facon T; Harding SJ; Moreau P; Leleu X
    Cancer; 2014 Dec; 120(24):3952-7. PubMed ID: 25116271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlations among different markers determined by immunochemical methods used for the diagnosis and monitoring of intact immunoglobulin multiple myeloma cases.
    Dogaru M; Lazăr V; Coriu D
    Roum Arch Microbiol Immunol; 2012; 71(4):183-200. PubMed ID: 23755700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients.
    Ludwig H; Milosavljevic D; Zojer N; Faint JM; Bradwell AR; Hübl W; Harding SJ
    Leukemia; 2013 Jan; 27(1):213-9. PubMed ID: 22955329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heavy/light chain specific immunoglobulin ratios provides no additional information than serum proteins electrophoresis and immunofixation for the diagnosis and the follow-up of intact immunoglobulin multiple myeloma patients.
    Beaumont-Epinette MP; Moreau C; Besnard S; Latute F; Collet N; Sebillot M; Grosbois B; Bendavid C; Guenet L; Decaux O
    Pathol Biol (Paris); 2015 Sep; 63(4-5):215-21. PubMed ID: 26319969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heavy/light chain assay in the monitoring of multiple myeloma.
    Ting HY; Sthaneshwar P; Bee PC; Shanmugam H; Lim M
    Pathology; 2019 Aug; 51(5):507-511. PubMed ID: 31253381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analytical performance and diagnostic potential of immunoassays determining intact immunoglobulin kappa/lambda ratios in monoclonal gammopathies.
    Eckold J; Poenisch W; Drogies T; Kratzsch J; Teupser D; Thiery J; Bruegel M
    Clin Lab; 2014; 60(9):1491-500. PubMed ID: 25291945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
    Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of serum immunoglobulin heavy/light chain ratio in patients with multiple myeloma in complete remission after autologous stem cell transplantation.
    Tovar N; Fernández de Larrea C; Elena M; Cibeira MT; Aróstegui JI; Rosiñol L; Filella X; Yagüe J; Bladé J
    Biol Blood Marrow Transplant; 2012 Jul; 18(7):1076-9. PubMed ID: 22430087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Analysis of the relationship of heavy/light chain pairs of immunoglobulin (Hevylite) to the results of gel electrophoresis and nefelometric examination of serum proteins at the time of multiple myeloma diagnosis].
    Ščudla V; Lochman P; Pika T; Zapletalová J; Minařík J; Bačovský J
    Cas Lek Cesk; 2015; 154(6):292-302. PubMed ID: 26750626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoglobulin heavy/light chain analysis enhances the detection of residual disease and monitoring of multiple myeloma patients.
    Batinić J; Perić Z; Šegulja D; Last J; Prijić S; Dubravčić K; Volarić L; Sertić D; Radman I; Bašić-Kinda S; Matišić D; Batinić D; Labar B; Nemet D
    Croat Med J; 2015 Jun; 56(3):263-71. PubMed ID: 26088851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reference change values of M-protein, free light chain and immunoglobulins in monoclonal gammopathy.
    Evliyaoglu O; van Helden J; Jaruschewski S; Imöhl M; Weiskirchen R
    Clin Biochem; 2019 Dec; 74():42-46. PubMed ID: 31526775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients.
    García de Veas Silva JL; Bermudo Guitarte C; Menéndez Valladares P; Rojas Noboa JC; Kestler K; Duro Millán R
    PLoS One; 2016; 11(11):e0166841. PubMed ID: 27893836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS.
    Katzmann JA; Clark R; Kyle RA; Larson DR; Therneau TM; Melton LJ; Benson JT; Colby CL; Dispenzieri A; Landgren O; Kumar S; Bradwell AR; Cerhan JR; Rajkumar SV
    Leukemia; 2013 Jan; 27(1):208-12. PubMed ID: 22781594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring IgA multiple myeloma: immunoglobulin heavy/light chain assays.
    Katzmann JA; Willrich MA; Kohlhagen MC; Kyle RA; Murray DL; Snyder MR; Rajkumar SV; Dispenzieri A
    Clin Chem; 2015 Feb; 61(2):360-7. PubMed ID: 25451866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.